EP4400171A2 — Use of valbenazine for treating schizophrenia or schizoaffective disorder
Assigned to Neurocrine Biosciences Inc · Expires 2024-07-17 · 2y expired
What this patent protects
Provided herein are methods for treating schizophrenia or schizoaffective disorder by administering to a subject in need thereof (S)-2-amino-3-methyl-butyric acid (2R,3R,1 1bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,I-a]isoquinolin-2-yl ester, or an isotopi…
USPTO Abstract
Provided herein are methods for treating schizophrenia or schizoaffective disorder by administering to a subject in need thereof (S)-2-amino-3-methyl-butyric acid (2R,3R,1 1bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,I-a]isoquinolin-2-yl ester, or an isotopic variant thereof, or a pharmaceutically acceptable salt or polymorph thereof.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.